A Stock Overview
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide.
Agilent Technologies Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$123.72|
|52 Week High||US$165.68|
|52 Week Low||US$112.52|
|1 Month Change||-3.43%|
|3 Month Change||4.17%|
|1 Year Change||-22.68%|
|3 Year Change||68.67%|
|5 Year Change||87.94%|
|Change since IPO||189.40%|
Recent News & Updates
Does Agilent Technologies (NYSE:A) Have A Healthy Balance Sheet?
Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Agilent Confirmed Its Leadership And Is Set For Further Gains (Technical Analysis)
Summary Agilent reached the price target I suggested in April and is now showing even more strength. The stock is a leader in its industry and the healthcare sector is among the strongest in 3 months. With 113% performance over the past 5 years, Agilent outperformed its reference index by almost seven times. The stock has most likely a 14% upside potential, with a price target seen at $160. Investment thesis Agilent Technologies (NYSE:A) lost about 37% of its value since its stock all-time high (ATH) at $179.57 on September 3, 2021, bottoming at $112.52 on June 22, 2022, showing significant relative strength since the beginning of May and increasing strong buy-side volume during the bottoming phase. The stock reached the price target I suggested in my first analysis and is now showing significant strength after a retracement to its most strong support levels. My most likely price target is set at $160, with 14% upside potential from its latest closing price. A quick look at the big picture The healthcare sector in the US is among the winners in the last 3 months, led by a rebound in biotechnology stocks, followed by companies in the diagnostics and research industry. finviz The NASDAQ Health Care Index (IXHC) bottomed on June 16 and mostly showed relative strength since, when compared to the main index, while recently consolidating after reaching its EMA200. Author, using TradingView Looking back even further, Agilent significantly outperformed its main reference indexes and funds, reporting 113.74% performance over the past 5 years, almost seven times the performance of the IXHC and more than double of the Health Care Select Sector SPDR (NYSEARCA:XLV). Author, using SeekingAlpha.com Where are we now? Since my last article 'Agilent: A Strong Leader With Great Opportunities', the stock broke the mentioned supports at $123 and further at $120, with a significant gap down on June 13, just before confirming its bottom on June 15. The stock has since formed a short-term reversal, confirming its price level over the EMA50, reaching the price target I set on April 15, and recently even confirming its level over the EMA200, while the latter is giving signs of flattening, which could confirm that the stock has formed a sound base from which continuing in its medium-term uptrend. Author, using TradingView Each important resistance has been overcome with conviction on higher volume, confirming the stock's relative strength, which seems now set for further strength, and may be confirmed by the MACD, which just crossed its signal line, pointing to positive momentum in the stock price action. The actual most important support level is set by the EMA200, while minor support can also be found at the recent overcome retracement level at $138.13 and $134.33. Further resistances are now located at $146.04 and the recent peak at $149. What is coming next I expect the stock to continue in its recent run, as the favorable momentum in its industry seems to be confirmed and the stock could attempt to overcome its recent highs. Source: Author, using TradingView The stock just completed its corrective phase, a new uptrend based on an Elliott motive phase has likely begun and is supported by the strong trend, set since the end of June. My calculations based on Fibonacci's theory, suggest the most likely price target at $160, as the first target at $139 has already been reached.
Agilent, Mettler-Toledo team up for solution to reduce errors in sample preparation
Agilent Technologies (NYSE:A) and Mettler-Toledo International (NYSE:MTD) are collaborating to reduce errors in sample preparation workflows for better chromatographic results. The integrated solution allows automatic and seamless transfer of weighing results and associated metadata from Mettler-Toledo LabX Balance software to Agilent's OpenLab software. The solution, which was launched in Munich in June, offers an LC or GC workflow aimed at eliminating common errors in the weighing process. "The seamless integration of balances and chromatography instruments in a digital and automated sample preparation and analysis process allows a drastic reduction or even elimination of transcription and calculation errors, significantly increasing lab productivity," said Mettler-Toledo CEO Patrick Kaltenbach.
|A||US Life Sciences||US Market|
Return vs Industry: A exceeded the US Life Sciences industry which returned -32.7% over the past year.
Return vs Market: A matched the US Market which returned -22.1% over the past year.
|A Average Weekly Movement||4.8%|
|Life Sciences Industry Average Movement||9.7%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||15.8%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: A is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: A's weekly volatility (5%) has been stable over the past year.
About the Company
Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide.
Agilent Technologies Fundamentals Summary
|A fundamental statistics|
Is A overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|A income statement (TTM)|
|Cost of Revenue||US$3.05b|
Last Reported Earnings
Jul 31, 2022
Next Earnings Date
|Earnings per share (EPS)||4.49|
|Net Profit Margin||19.94%|
How did A perform over the long term?See historical performance and comparison
0.7%Current Dividend Yield
Does A pay a reliable dividends?See A dividend history and benchmarks
|Agilent Technologies dividend dates|
|Ex Dividend Date||Oct 03 2022|
|Dividend Pay Date||Oct 26 2022|
|Days until Ex dividend||4 days|
|Days until Dividend pay date||27 days|
Does A pay a reliable dividends?See A dividend history and benchmarks
Is A undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score 3/6
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Below Fair Value
Significantly Below Fair Value
Key Valuation Metric
Which metric is best to use when looking at relative valuation for A?
Other financial metrics that can be useful for relative valuation.
|What is A's n/a Ratio?|
Price to Earnings Ratio vs Peers
How does A's PE Ratio compare to its peers?
|A PE Ratio vs Peers|
|Company||PE||Estimated Growth||Market Cap|
IQV IQVIA Holdings
MTD Mettler-Toledo International
WST West Pharmaceutical Services
A Agilent Technologies
Price-To-Earnings vs Peers: A is good value based on its Price-To-Earnings Ratio (27.6x) compared to the peer average (27.7x).
Price to Earnings Ratio vs Industry
How does A's PE Ratio compare vs other companies in the US Life Sciences Industry?
Price-To-Earnings vs Industry: A is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the US Life Sciences industry average (23.8x)
Price to Earnings Ratio vs Fair Ratio
What is A's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
|Current PE Ratio||27.6x|
|Fair PE Ratio||26x|
Price-To-Earnings vs Fair Ratio: A is expensive based on its Price-To-Earnings Ratio (27.6x) compared to the estimated Fair Price-To-Earnings Ratio (26x).
Share Price vs Fair Value
What is the Fair Price of A when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: A ($123.72) is trading below our estimate of fair value ($133.51)
Significantly Below Fair Value: A is trading below fair value, but not by a significant amount.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.
Discover undervalued companies
How is Agilent Technologies forecast to perform in the next 1 to 3 years based on estimates from 17 analysts?
Future Growth Score2/6
Future Growth Score 2/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: A's forecast earnings growth (10.4% per year) is above the savings rate (1.9%).
Earnings vs Market: A's earnings (10.4% per year) are forecast to grow slower than the US market (14.8% per year).
High Growth Earnings: A's earnings are forecast to grow, but not significantly.
Revenue vs Market: A's revenue (6% per year) is forecast to grow slower than the US market (7.6% per year).
High Growth Revenue: A's revenue (6% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: A's Return on Equity is forecast to be high in 3 years time (28.2%)
Discover growth companies
How has Agilent Technologies performed over the past 5 years?
Past Performance Score6/6
Past Performance Score 6/6
Growing Profit Margin
Earnings vs Industry
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: A has high quality earnings.
Growing Profit Margin: A's current net profit margins (19.9%) are higher than last year (16.1%).
Past Earnings Growth Analysis
Earnings Trend: A's earnings have grown by 19.2% per year over the past 5 years.
Accelerating Growth: A's earnings growth over the past year (34.1%) exceeds its 5-year average (19.2% per year).
Earnings vs Industry: A earnings growth over the past year (34.1%) exceeded the Life Sciences industry 15.6%.
Return on Equity
High ROE: A's Return on Equity (26.1%) is considered high.
Discover strong past performing companies
How is Agilent Technologies's financial position?
Financial Health Score5/6
Financial Health Score 5/6
Short Term Liabilities
Long Term Liabilities
Financial Position Analysis
Short Term Liabilities: A's short term assets ($3.7B) exceed its short term liabilities ($1.9B).
Long Term Liabilities: A's short term assets ($3.7B) exceed its long term liabilities ($3.5B).
Debt to Equity History and Analysis
Debt Level: A's net debt to equity ratio (36%) is considered satisfactory.
Reducing Debt: A's debt to equity ratio has increased from 45.1% to 57.2% over the past 5 years.
Debt Coverage: A's debt is well covered by operating cash flow (44.8%).
Interest Coverage: A's interest payments on its debt are well covered by EBIT (20.7x coverage).
Discover healthy companies
What is Agilent Technologies's current dividend yield, its reliability and sustainability?
Dividend Score 0/6
Cash Flow Coverage
Current Dividend Yield
Upcoming Dividend Payment
Dividend Yield vs Market
|Agilent Technologies Dividend Yield vs Market|
|Company (Agilent Technologies)||0.7%|
|Market Bottom 25% (US)||1.6%|
|Market Top 25% (US)||4.6%|
|Industry Average (Life Sciences)||0.3%|
|Analyst forecast in 3 Years (Agilent Technologies)||0.8%|
Notable Dividend: A's dividend (0.68%) isn’t notable compared to the bottom 25% of dividend payers in the US market (1.67%).
High Dividend: A's dividend (0.68%) is low compared to the top 25% of dividend payers in the US market (4.69%).
Stability and Growth of Payments
Stable Dividend: A is not paying a notable dividend for the US market, therefore no need to check if payments are stable.
Growing Dividend: A is not paying a notable dividend for the US market, therefore no need to check if payments are increasing.
Earnings Payout to Shareholders
Earnings Coverage: A is not paying a notable dividend for the US market.
Cash Payout to Shareholders
Cash Flow Coverage: A is not paying a notable dividend for the US market.
Discover strong dividend paying companies
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Mike McMullen (61 yo)
Mr. Michael R. McMullen, also known as Mike, has been the President of Agilent Technologies, Inc., since September 17, 2014 and Chief Executive Officer since March 18, 2015. Mr. McMullen has been a Directo...
CEO Compensation Analysis
|Mike McMullen's Compensation vs Agilent Technologies Earnings|
|Date||Total Comp.||Salary||Company Earnings|
|Jul 31 2022||n/a||n/a|
|Apr 30 2022||n/a||n/a|
|Jan 31 2022||n/a||n/a|
|Oct 31 2021||US$16m||US$1m|
|Jul 31 2021||n/a||n/a|
|Apr 30 2021||n/a||n/a|
|Jan 31 2021||n/a||n/a|
|Oct 31 2020||US$14m||US$1m|
|Jul 31 2020||n/a||n/a|
|Apr 30 2020||n/a||n/a|
|Jan 31 2020||n/a||n/a|
|Oct 31 2019||US$13m||US$1m|
|Jul 31 2019||n/a||n/a|
|Apr 30 2019||n/a||n/a|
|Jan 31 2019||n/a||n/a|
|Oct 31 2018||US$12m||US$1m|
|Jul 31 2018||n/a||n/a|
|Apr 30 2018||n/a||n/a|
|Jan 31 2018||n/a||n/a|
|Oct 31 2017||US$10m||US$1m|
|Jul 31 2017||n/a||n/a|
|Apr 30 2017||n/a||n/a|
|Jan 31 2017||n/a||n/a|
|Oct 31 2016||US$9m||US$1m|
|Jul 31 2016||n/a||n/a|
|Apr 30 2016||n/a||n/a|
|Jan 31 2016||n/a||n/a|
|Oct 31 2015||US$7m||US$846k|
Compensation vs Market: Mike's total compensation ($USD15.97M) is about average for companies of similar size in the US market ($USD13.05M).
Compensation vs Earnings: Mike's compensation has been consistent with company performance over the past year.
Experienced Management: A's management team is seasoned and experienced (7.3 years average tenure).
Experienced Board: A's board of directors are considered experienced (7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: A insiders have only sold shares in the past 3 months.
Recent Insider Transactions
|09 Sep 22||SellUS$802,571||Jacob Thaysen||Individual||5,839||US$137.45|
|08 Sep 22||SellUS$336,641||Padraig McDonnell||Individual||2,506||US$134.33|
|30 Jun 22||SellUS$118,625||Padraig McDonnell||Individual||1,000||US$118.63|
|02 Jun 22||SellUS$749,179||Jacob Thaysen||Individual||5,879||US$127.43|
|18 Mar 22||SellUS$164,814||Michael Tang||Individual||1,210||US$136.21|
|29 Dec 21||SellUS$590,709||Dominique Grau||Individual||3,669||US$161.00|
|20 Dec 21||SellUS$18,373,168||Michael McMullen||Individual||123,459||US$148.82|
|02 Dec 21||SellUS$121,512||Rodney Gonsalves||Individual||800||US$151.89|
|30 Nov 21||SellUS$106,274||Rodney Gonsalves||Individual||699||US$152.04|
|Owner Type||Number of Shares||Ownership Percentage|
|State or Government||134,901||0.05%|
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
|Ownership||Name||Shares||Current Value||Change %||Portfolio %|
Agilent Technologies, Inc.'s employee growth, exchange listings and data sources
- Name: Agilent Technologies, Inc.
- Ticker: A
- Exchange: NYSE
- Founded: 1999
- Industry: Life Sciences Tools and Services
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: US$36.626b
- Shares outstanding: 296.04m
- Website: https://www.agilent.com
Number of Employees
- Agilent Technologies, Inc.
- 5301 Stevens Creek Boulevard
- Santa Clara
- United States
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|A||NYSE (New York Stock Exchange)||Yes||Common Stock||US||USD||Nov 1999|
|AG8||DB (Deutsche Boerse AG)||Yes||Common Stock||DE||EUR||Nov 1999|
|A *||BMV (Bolsa Mexicana de Valores)||Yes||Common Stock||MX||MXN||Nov 1999|
|0HAV||LSE (London Stock Exchange)||Yes||Common Stock||GB||USD||Nov 1999|
|AG8||ETLX (Eurotlx)||Yes||Common Stock||IT||EUR||Nov 1999|
|A||BVL (Bolsa de Valores de Lima)||Yes||Common Stock||PE||USD||Nov 1999|
|A1GI34||BOVESPA (Bolsa de Valores de Sao Paulo)||BDR EACH 2 REPR 1 SHS UNSPON||BR||BRL||Jan 2020|
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2022/09/28 00:00|
|End of Day Share Price||2022/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.